Binding molecules against BCMA and uses thereof

US11492409B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Aida Abujoub · Winchester, US
• John W. Blankenship · Acton, US
• Tony Fleming · Stow, US
• Brian Holmberg · Somerville, US
• Connie Hong · Somerville, US
• Lu Huang · Riverdale, US
• Haihui Lu · Cambridge, US

Key dates

• Filing date: May 30, 2019
• Grant date: Nov 8, 2022
• Expiry date: Feb 10, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.